X4 Pharmaceuticals, Inc. (XFOR)
NASDAQ: XFOR · Real-Time Price · USD
0.467
-0.006 (-1.33%)
At close: Feb 21, 2025, 4:00 PM
0.470
+0.003 (0.62%)
After-hours: Feb 21, 2025, 6:03 PM EST
X4 Pharmaceuticals Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for X4 Pharmaceuticals stock have an average target of 3.50, with a low estimate of 1.50 and a high estimate of 5.00. The average target predicts an increase of 649.30% from the current stock price of 0.47.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for X4 Pharmaceuticals stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 4 | 4 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $1.5 | Strong Buy | Reiterates | $1.5 | +221.13% | Feb 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $1.5 | Strong Buy | Reiterates | $1.5 | +221.13% | Jan 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $5 → $1.5 | Strong Buy | Maintains | $5 → $1.5 | +221.13% | Nov 14, 2024 |
| Stifel | Stifel | Strong Buy Maintains $5 → $4 | Strong Buy | Maintains | $5 → $4 | +756.35% | Nov 14, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +970.43% | Jun 28, 2024 |
Financial Forecast
Revenue This Year
2.24M
Revenue Next Year
15.46M
from 2.24M
Increased by 590.67%
EPS This Year
-0.16
from -0.57
EPS Next Year
-0.51
from -0.16
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 2.8M | 21.0M | 136.2M | |||
| Avg | 2.2M | 15.5M | 62.3M | |||
| Low | 1.9M | 7.6M | 19.4M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | 837.9% | 780.7% | |||
| Avg | - | 590.7% | 302.7% | |||
| Low | - | 241.4% | 25.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.15 | -0.33 | -0.20 | |||
| Avg | -0.16 | -0.51 | -0.40 | |||
| Low | -0.17 | -0.60 | -0.55 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.